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Background: Based on previous observations a potential resort in the therapy of the particularly radioresistant
glioma would be its treatment with unsaturated fatty acids (UFAs) combined with irradiation.
Methods: We evaluated the effect of different UFAs (arachidonic acid (AA), docosahexaenoic acid (DHA),
gamma-linolenic acid (GLA), eicosapentaenoic acid (EPA) and oleic acid (OA)) on human U87 MG glioma cell line by
classical biochemical end-point assays, impedance-based, real-time cellular and holographic microscopic analysis. We
further analyzed AA, DHA, and GLA at morphological, gene and miRNA expression level.
Results: Corresponding to LDH-, MTS assays and real-time cytoxicity profiles AA, DHA, and GLA enhanced the radio
sensitivity of glioma cells. The collective application of polyunsaturated fatty acids (PUFAs) and irradiation significantly
changed the expression of EGR1, TNF-α, NOTCH1, c-MYC, TP53, HMOX1, AKR1C1, NQO1, while up-regulation of GADD45A,
EGR1, GRP78, DDIT3, c-MYC, FOSL1 were recorded both in response to PUFA treatment or irradiation alone. Among the
analyzed miRNAs miR-146 and miR-181a were induced by DHA treatment. Overexpression of miR-146 was also
detected by combined treatment of GLA and irradiation.
Conclusions: Because PUFAs increased the radio responsiveness of glioma cells as assessed by biochemical and
cellular assays, they might increase the therapeutic efficacy of radiation in treatment of gliomas. We demonstrated that
treatment with DHA, AA and GLA as adjunct to irradiation up-regulated the expression of oxidative-stress and
endoplasmic reticulum stress related genes, and affected NOTCH1 expression, which could explain their additive effects.
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Glioblastoma is among the most lethal tumor types, the
median survival time of patients following diagnosis is less
than two years. Glioma is the most common malignancy
of the central nervous system in adults [1]. Designing new
therapeutic methods for treating glioblastoma remains an
important task of the research community, due to its high
resistance to irradiation and chemotherapy. Currently, the
primary method for treatment of glioblastoma is surgical
resection in combination with radiotherapy and in several* Correspondence: puskas.szbk@gmail.com
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unless otherwise stated.cases chemotherapy [2-4]. Unfortunately, due to the radio-
resistance of glioma-initiating cells (cells with cancer stem
cell characteristics), the rate of recurrence is extremely
high [5].
Previous studies have pointed out that PUFAs are useful
as adjuncts in cancer treatment beside irradiation and
chemotherapy, both in vitro and in vivo [6-11]. Arachi-
donic acid (AA, 20:4n-6), docosahexaenoic acid (DHA,
22:6n-3), gamma-linolenic acid (GLA, 18:3n-6) and eicosa-
pentaenoic acid (EPA, 20:5n-3) per se induced apoptosis of
cancerous cells [6-9]. According to studies on glioma
spheroids grown on collagen gels and on several glioma
cell lines (C6, U373, U87 MG) GLA treatment was cyto-
toxic, while it did not influence normal cells [11]. In vivo,
GLA treatment did not influence normal brain tissue andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Antal et al. Lipids in Health and Disease 2014, 13:142 Page 2 of 15
http://www.lipidworld.com/content/13/1/142it caused the regression of glioblastomas in human pa-
tients, without detectable side-effects or acute inflamma-
tory response [10-12]. In a pilot study, GLA was applied as
a therapeutic agent after surgery; it was administered by
intracranial infusion, and it was found that it is neuropro-
tective with minimal side-effects. Experiments performed
on rat and human brains suggest that GLA infusion
through the intraparenchymal route is an effective method,
it could appreciably expand the life-expectancy of glioblast-
oma patients, it could even double the survival period from
2 to 4 years [11,13,14].
Leary et al. found that GLA acts more selectively on hu-
man oesophageal carcinoma cells, than AA and EPA [15].
GLA treatment diminished anti-oxidant levels in tumor
cells which may be beneficial, because anti-oxidants in-
hibit the apoptotic effect of GLA on cancer cells. At the
same time, the genotoxic and cytotoxic effect of chemo-
therapeutics and radiation was attenuated by GLA treat-
ment [11].
In a clinical study, EPA and DHA supplementation
was found to be beneficial in lung cancer treatment [16].
ω-3 PUFAs facilitated the uptake of chemotherapeutic
drugs, in vitro enhanced their cytotoxic effect. EPA and
DHA supplementation associated with the administra-
tion of several chemotherapeutics diminished tumor size
and alleviated side effects [17].
It was described that PUFAs can increase the cytotox-
icity of numerous chemotherapeutics in vitro, in brain,
lung, breast, sarcoma, lymphocytic, colon human cell cul-
tures [17-20]. PUFAs also inhibited cachexia in animal
models; suppressed neoplastic transformation; inhibited
angiogenesis and metastasis [21].
One possibility to achieve a more intense antitumor
effect would be the combination of fatty acids with
radiotherapy, which was proven to be beneficial both
in vivo and in vitro. DHA enhanced the responsiveness
of mammary tumors to ionizing radiation, and it did not
influence the radio-sensitivity of normal tissue [22]. The
exact mechanism by which DHA in combination with
radiotherapy exerts its specific effect on tumors is yet
unknown, but lipid peroxidation can be a contributing
factor [19,22]. The same hypothesis could also stand for
GLA treatment. Furthermore, GLA treatment protected
mice bone marrow cells from irradiation-induced DNA
damage [Das, 2007 = reference 11]. GLA could also
sensitize astrocytoma to radiotherapy, while on normal
cells it had a cytoprotective effect [10,11]. GLA, AA and
EPA had a synergistic effect with irradiation on C6 gli-
oma cells, enhancing the rate of apoptosis [13].
During the present study we investigated the inter-
action between UFAs and irradiation on human U87
MG glioma cell line, by biophysical and biochemical as-
says, holographic imaging and quantitative PCR based
assays.The molecular pathways that are affected in glioblast-
oma, the genetic interaction network through which
UFA treatment and irradiation can selectively kill cancer
cells is still undetermined. The assessment of genes and
miRNAs with altered expression due to PUFA treatment
and irradiation can be the foundation of improved and
more effective therapies.
Results
LDH-, MTS assay and impedance based toxicity analysis
(RT-CES assay) were performed on U87 MG cells to rec-
ord the effects of UFA treatment, irradiation and their
combination (Figures 1, 2, 3, 4 and 5).
The RT-CES assay permitted us to investigate the kin-
etics of cell growth and proliferation and determine the
onset of changes on the cells treated and/or irradiated
with UFAs. RT-CES results were validated with two bio-
chemical end-point assays, LDH and MTS measure-
ments. Those combined treatments that showed at least
an additive effect compared to UFA treatment or irradi-
ation alone were selected for further validation and ana-
lysis. For the evaluation of morphological changes and
alterations in gene and miRNA expression induced by
UFAs and/or irradiation a 48 hour incubation period
was selected (Figures 1, 2, 3, 4 and 5).
Analysis of cell metabolism and cell growth by real time
and end point assays
The RT-CES assay permits non-invasive, dynamic moni-
toring of living cells [23,25]. This is a real-time micro-
electronic sensor-based platform, which measures the
relative change of impedance of electrodes in individual
wells of special culture plates. Attached cells in the wells
change the impedance of the electrodes by acting as insu-
lators, thus the assay enables the continuous measurement
of cell attachment and proliferation [23,25]. The effects of
five selected fatty acids alone and in combination with
two doses of irradiation (5 Gy and 10 Gy) are shown in
Figures 1, 2, 3, 4 and 5. Fatty acid pre-treatment and ir-
radiation were carried out 24 hours after cell seeding.
According to our RT-CES, LDH and MTS assay re-
sults, irradiation with 5 or 10 Gy changed cell prolifera-
tion, viability and LDH activity in a dose dependent
manner (Figures 1, 2, 3, 4 and 5, green curves on panel
A, and the first 3 bars on panel D and E).
Four of the tested five fatty acids, namely AA, DHA,
GLA and OA decreased cell viability, while EPA had no
effect in the tested concentration range.
LDH and MTS assays showed a well-defined concen-
tration response when only AA treatment was applied
(Figure 1). With the real time assay considerable change
could only be recorded at 75 μM. All three assays
showed an additive effect of the combined treatments at
5 Gy irradiation and 25 μM AA.
Figure 1 Biochemical and biophysical assays on irradiated and AA treated glioma cell line. The effect of AA on impedance based toxicity
profiles (A-C), LDH activity (D) and cell viability (E) on irradiated U87 MG cells. */** - significant (p < 0.05/ p < 0.01) alteration compared to control
cells, +/++ - significant (p < 0.05/ p < 0.01) compared to cells exposed to irradiation (5 or 10 Gy, dose- matched), #/## - significant (p < 0.05/ p < 0.01)
compared to cells subjected to AA (concentration matched).
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only at 75 μM, while an appreciable drop in cell viability
and LDH activity was recorded at 25 μM concentration
(Figure 2). Significant additive effects could not be detected
in the MTS assay, while the 25 μM treatment combined
with 5 or 10 Gy dose showed synergism in both the LDH
and RT-CES assay.
50 and 75 μM GLA did not alter the kinetics of cell
index, while combination with 5 Gy irradiation reduced
the rate of proliferation of U87 MG cells (Figure 3).
GLA treatment and irradiation also influenced the MTS
and LDH activity of U87 MG cells significantly (Figure 3).
In case of exposure to 75 μM GLA and 10 Gy we noticed
a strong additive effect on LDH activity.
Combined treatment of U87 MG cells with EPA and
irradiation did not affect the impedance based toxicity
profiles compared to irradiation alone (Figure 4). The
LDH assay showed a significant decrease in signal at 75
and 100 μM EPA concentrations compared to 5 Gy, but
this change was not confirmed by the other two assays.
In contrast with other UFAs 100-200 μM OA in-
creased cell index values compared to respective con-
trols, that reflect increased proliferation (Figure 5),
however this was not confirmed by the end-point assays.
The observed signal increase may be due to a change incell morphology following OA administration. Treat-
ment with 400 μM resulted in complete cell death con-
firmed by all three methods.
Based on the results presented above, we have chosen
three PUFAs, namely, AA, DHA and GLA for further
investigation.
Morphological analysis of glioma cell line treated with
AA, DHA, GLA and irradiation
Holographic and phase contrast (3-3 frames) pictures
were taken with HoloMonitor™ M3 (Figure 6). 600,000
cells were exposed to 25 μM AA, 25 μM DHA or 50 μM
GLA alone or in combination with irradiation (10 Gy).
Based on holographic and phase contrast images,
treatment with 25 μM AA or the combination of 25 μM
AA and 10 Gy was the most effective in terms of anti-
proliferative effects, although irradiation did not cause a
significant decrease in cell number and confluence com-
pared to only AA treatment (Figures 6 and 7). DHA and
GLA treatment enhanced the effect of irradiation, while
alone they did not alter cell number and confluence
(Figure 7). After a more thorough investigation of these
parameters the synergistic effect of PUFA and irradiation
is evident, exposure to 10 Gy did not alter cell number
and confluence, while co-treatment induced a significant
Figure 2 Biochemical and biophysical assays on irradiated and DHA treated glioma cell line. The effect of DHA on impedance based
toxicity profiles (A-C), LDH activity (D) and cell viability (E) on irradiated U87 MG cells.*/** - significant (p < 0.05/ p < 0.01) alteration compared to
control cells, +/++ - significant (p < 0.05/ p < 0.01) compared to cells exposed to irradiation (5 or 10 Gy, dose- matched), #/## - significant
(p < 0.05/ p < 0.01) compared to cells treated with DHA (concentration matched).
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thickness and irregularity) indicating cell death also showed
added effects of the combined treatment (Figure 7). Expos-
ure to PUFAs and irradiation increased cell thickness while
irregularity decreased. The alteration in the latter two pa-
rameters suggested that cells became rounded and started
to detach from the surface showing a typical phenotype of
dying cells. Exposure to AA, 10 Gy, the combination of
AA + 10 Gy, DHA + 10 Gy and GLA + 10 Gy significantly
increased cell thickness (Figure 7). Average cell irregularity
is also diminished by AA alone, AA + 10 Gy, and GLA +
10 Gy treatment (Figure 7).
Our morphological analysis demonstrates that co-
exposure to PUFAs and irradiation can cause synergistic
changes in phenotypic parameters of U87 MG cells.
Gene expression analysis of PUFA treated and irradiated
U87 MG cells
In our previous paper we have shown that in several gli-
oma cell lines (U373, GBM2, GBM5) exposure to AA,
DHA and GLA differentially modify the expression of
miRNAs and their corresponding target genes inducing
apoptosis [7].
After treatment of U87 MG cells with PUFA or irradi-
ation we investigated the expression of oxidative stressrelated genes (HMOX1, AKR1C1, NQO1), endoplasmic
reticulum stress response genes (GRP78, DDIT3), early re-
sponse genes (EGR1, TNF-α, c-FOS, FOSL1), an oncogene
(c-MYC) and of TP53, GADD45A and NOTCH1 (Figures 8
and 9). We noticed alteration in the expression of every
gene at least in one condition: PUFA treatment or irradi-
ation. PUFA treatment and 10 Gy had a significant effect
in case of EGR1, TNF-α, NOTCH1, c-FOS, c-MYC, TP53,
HMOX1, AKR1C1 and NQO1 compared to irradiated cells
(Figures 8 and 9). Addition of PUFAs as adjuvants to 10
Gy did not alter the effect of irradiation on endoplasmic
reticulum stress response (Figure 8, GRP78 and DDIT3).
On the other hand, the expression of oxidative stress re-
sponse related genes (Figure 8, HMOX1, AKR1C1 and
NQO1) were significantly up-regulated due to co-exposure
to PUFAs and 10 Gy compared to the case when cells
were just irradiated.
Over-expression of TP53 and c-MYC could be noticed
when U87 MG cells were irradiated (Figure 9). When
AA was added to 10 Gy, TP53 expression decreased sig-
nificantly, while c-MYC was up-regulated (Figure 9). In
case of c-MYC, AA treatment was enough to signifi-
cantly induce its expression.
Application of GLA or 10 Gy up-regulated NOTCH1 ex-
pression. In contrast, after combined treatment NOTCH1
Figure 3 Biochemical and biophysical assays on irradiated and GLA treated glioma cell line. The effect of GLA on impedance based
toxicity profiles (A-C), LDH activity (D) and cell viability (E) on irradiated U87 MG cells. */** - significant (p < 0.05/ p < 0.01) alteration compared
to control cells, +/++ - significant (p < 0.05/ p < 0.01) compared to cells exposed to irradiation (5 or 10 Gy, dose- matched), #/## - significant
(p < 0.05/ p < 0.01) compared to cells treated with GLA (concentration matched).
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sion of GADD45A increased significantly after exposure to
AA or 10 Gy (Figure 9).
10 Gy caused significant over-expression in case of every
early-response gene (EGR1, TNF-α, FOSL1, c-FOS) we in-
vestigated. This is likely due to their radiation sensitive
CArG promoters (Figure 9). AA, DHA or GLA treatment
increased EGR1 expression significantly. When cells were
co-treated with AA and 10 Gy, EGR1, TNF-α, c-FOS ex-
pression decreased significantly compared to the irradiated
sample (Figure 9). This could not be noted in case of
DHA and GLA. When cells were exposed to GLA and 10
Gy an additive effect was detected in EGR1 expression
(Figure 9). PUFA treatment did not influence TNF-α and
c-FOS expression in a significant manner (Figure 9). PUFA
treatment and application of PUFAs with irradiation in-
duced over-expression of FOSL1 (Figure 9).
We also investigated the effect of the selected PUFAs
and irradiation on the following genes: SIRT1, MMP14,
TGFBI, TIMP3, but alteration in the expression of these
genes was not detected (data not shown).
Irradiation with 10 Gy and PUFA treatment did not
affect the expression of miR-34a, miR-96, miR-148a,
miR-148b and miR-152 significantly (Additional file 1:
Figure S1). miR-146a was up-regulated when cells weretreated with DHA, while its expression decreased when
it was exposed to GLA (Additional file 1: Figure S1). In
case of combined exposure to irradiation and GLA the
expression increased significantly compared to irradiated
or GLA treated cells. miR-181a expression significantly
increased following DHA treatment (Additional file 1:
Figure S1).Discussion
Radiotherapy is the most often applied treatment after
surgical resection of glioblastoma. Application PUFAs as
adjuncts enhance eradication of glioma cells. Numerous
in vitro and in vivo experiments have shown that PUFAs
may increase the tumoricidal effect of radiotherapy
[19,22,26]. PUFAs have little or no cytotoxic effect on nor-
mal cells, and at the same time, they diminish the deteri-
orative effect of irradiation. In our study, we treated U87
MG cells with UFAs (AA, DHA, GLA, OA, EPA) at differ-
ent concentrations and cell viability, LDH activity, cell
growth, cell morphology and gene expression changes
were analyzed. Besides classical end-point assays (LDH
measurements and MTS assay) we used the RT-CES sys-
tem for real-time cellular analysis. This label-free and
non-invasive method measures impedance and determines
Figure 4 Biochemical and biophysical assays on irradiated and EPA treated glioma cell line. The effect of EPA on impedance based
toxicity profiles (A-C), LDH activity (D) and cell viability (E) on irradiated U87 MG cells. */** - significant (p < 0.05/ p < 0.01) alteration compared
to control cells, +/++ - significant (p < 0.05/ p < 0.01) compared to cells exposed to irradiation (5 or 10 Gy, dose- matched), #/## - significant
(p < 0.05/ p < 0.01) compared to cells treated with EPA (concentration matched).
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ity, adherence and cell growth [23,25].
We demonstrated that AA, DHA, GLA and OA treat-
ment decreased the proliferation rate of U87 MG glioma
cells and in correlation with the cytotoxic effects, de-
creased the total LDH activity that could be recorded
(Figure 1, 2, 3 and 5). EPA is an exception: it did not de-
crease the proliferation rate and LDH activity at the
tested concentration range (Figure 4).
AA treatment dramatically decreased cell viability and
LDH activity after 72 hours (Figure 1). Based on similar
effects against glioma cells AA was considered a possible
therapeutic PUFA agent [27]. When cells are irradiated
and treated with AA at the same time, LDH activity,
mitochondrial dehydrogenase activity, were significantly
decreased (Figure 1). We also detected a decrease in
normalized cell index, which is an indicator of cell pro-
liferation. This was more pronounced when AA was ap-
plied in combination with irradiation. From these results
we assume that AA treatment would hold promise in
glioblastoma radiotherapy as an adjunct.
Previously it was published that 20-50 μM DHA was
cytotoxic to Neuro2a cells, and the concentration range
below 10 μM inhibited apoptosis, without any detectable
toxic effects [28]. We made similar observations: 25-75μM DHA diminished the proliferation rate and altered
the metabolism of U87 MG cells (Figure 2). DHA treat-
ment had a distinct effect on medulloblastoma (DAOY
and D283) cells compared to glioma cells (U87 MG and
U138) regarding cell proliferation: it did not affect gli-
oma cells, while it inhibited proliferation of medulloblas-
toma cells [29].
In concert with our results related to GLA (Figure 5),
similar proliferation inhibition was reported with C6 gli-
oma cells [30].They found that in tumors treated with
GLA and EPA the mitochondrial membrane potential,
an indicator of apoptosis, decreased significantly [30,31].
In our study GLA diminished cell viability and LDH ac-
tivity of U87 MG cells, and increased the radio sensitiv-
ity of this cell line. Similarly, GLA was found to be
cytotoxic to rat 36B10 astrocytoma cells in other studies
[32]. 10-50 μM GLA significantly increased cell prolifer-
ation at the outer layer of glioma spheroids, enhancing
invasion [33]. In contrast, we found that 50-75 μM GLA
did not alter the proliferation rate of U87 MG cells
(Figure 3). It was reported that GLA selectively induced
apoptosis in spheroids and concentrations that exceed
100 μM inhibited proliferation, thus reduced invasion
[33]. Similarly, we found that 100 μM GLA diminished
the proliferation rate of U87 MG cells. Interestingly,
Figure 5 Biochemical and biophysical assays on irradiated and OA treated glioma cell line. The effect of OA on impedance based toxicity
profiles (A-C), LDH activity (D) and cell viability (E) on irradiated U87 MG cells.*/** - significant (p < 0.05/ p < 0.01) alteration compared to control
cells, +/++ - significant (p < 0.05/ p < 0.01) compared to cells exposed to irradiation (5 or 10 Gy, dose- matched), #/## - significant (p < 0.05/ p < 0.01)
compared to cells treated with OA (concentration matched).
Figure 6 Representative images of morphology of U87 MG cells treated with PUFAs and subjected to irradiation. Phase contrast images
were taken 48 hours after treatment with 25 μM AA, 25 μM DHA, 50 μM GLA and irradiation with 10 Gy.
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Figure 7 The effect of PUFAs and irradiation on cell number, confluence, average cell thickness and average cell irregularity. Cells were
treated for 48 hours with 25 μM AA; 25 μM DHA and 50 μM GLA and a part of the samples were submitted to 10 Gy irradiation. Abbreviations: */** -
significant (p < 0.05/p < 0.01) difference between control cells and treated cells, +/++ significant (p < 0.05/ p < 0.01) difference between cells exposed
only to 10 Gy and U87 MG cells co-treated with PUFA and 10 Gy, #/## significant (p < 0.05/ p < 0.01) difference between cells treated solely with PUFAs
and U87 MG cells co-treated with PUFA and 10 Gy (type and concentration matched).
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therapy, proliferation and LDH activity of U87 MG cells
were reduced (Figure 3). Previously, it was found that
GLA acted selectively on tumor cells, it had low neuro-
toxicity and it may even protect normal tissue from the
cytotoxic effect of irradiation or chemotherapy [10,11].
Therefore, the additive effects of GLA with irradiation,
its possible selectivity against tumor cells and even the
protection of normal tissues against irradiation would
make GLA an ideal candidate for combined therapy as
previously indicated earlier [10,11].
Interestingly, we found that at lower OA concentrations
(100-200 μM) normalized cell index increased (Figure 5).
This suggested elevated proliferation, although this was
not confirmed with the end-point assays. At higher con-
centrations (400 μM) OA diminished cell proliferation
soon after treatment as recorded by using the real-time
cellular analysis (Figure 5). A similar concentration of OA
(500 μM) influenced cell proliferation in a different man-
ner depending on cell type: it inhibited cell growth onFigure 8 Gene expression analysis of PUFA treated and irradiated glio
PUFAs, than incubated for 48 hours. Gene expression of oxidative stress rel
response genes (GRP78, DDIT3) were determined with RT-PCR. Abbreviation
GLA - 50 μM gamma linolenic acid. Abbreviations: */** significant (p < 0.05
cells; #/## - significant (p < 0.05/ p < 0.01) difference between Ct values of
Gy at the same time.LNCaP prostate cells, it enhanced cell proliferation in case
of breast cancer cell lines (MCF-7 and MDA-MB-231)
and it had no effect on a non-tumorogenic epithelial cell
line (MCF10A) [34,35]. Our results showed no benefit
using OA along with irradiation.
Previously, it was reported that EPA, similarly to GLA,
protected rat hippocampus from the harmful effect of
LPS-induced inflammation [36], therefore in case of addi-
tive effects of EPA and irradiation one could predict en-
hanced therapeutic effects. Under our conditions EPA
treatment (50-100 μM) did not affect LDH activity and
cell viability. Moreover, when it was used as an adjunct
with 5 Gy or 10 Gy a significant, but very moderate
change in cell metabolism could be detected (Figure 4). As
assessed by using real-time cell analysis technology, EPA
had no effect on normalized cell index of U87 MG cells
even when it was applied in combination with 5 or 10 Gy
irradiation (Figure 5). From these results we assume that
EPA treatment would not be good candidate as an adjunct
in glioblastoma radiotherapy.ma cell line. U87 MG cells were irradiated with 10 Gy, treated with
ated genes (HMOX1, AKR1C1, NQO1) and endoplasmic reticulum stress
s: AA - 25 μM arachidonic acid; DHA - 25 μM docosahexaenoic acid;
/ p < 0.01) difference between Ct values of control cells and treated
cells exposed to 10 Gy and U87 MG cells subjected to PUFAs and 10
Figure 9 Gene expression analysis of PUFA treated and irradiated glioma cell line. U87 MG cells were irradiated with 10 Gy, treated with
polyunsaturated fatty acids (PUFAs) and incubated for 48 hours. Gene expression of c-MYC, TP53 (p53), potential therapeutic targets (NOTCH1,
GADD45A, EGR1) and early response genes (EGR1,TNF-α, FOSL1, c-FOS) were determined with RT-PCR. Abbreviations: AA - 25 μM arachidonic acid;
DHA - 25 μM docosahexaenoic acid; GLA - 50 μM gamma linolenic acid. Abbreviations: */** - significant (p < 0.05/ p < 0.01) difference between
Ct values of control cells and treated cells. #/## - significant (p < 0.05/ p < 0.01) difference between Ct values of cells exposed to 10 Gy and U87
MG cells subjected to PUFAs and 10 Gy at the same time.
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surements and previously published data we could con-
clude that among the UFA we studied, DHA, GLA and
AA may provide benefit as therapeutic adjuncts in the
treatment of malignant brain tumor with radiation (re-
sults are summarized in Additional file 2: Table S2).Morphological analysis of glioma cell line treated with
AA, DHA, GLA and irradiation
Holographic microscopy permits the label-free and
non-invasive visualization of living cells. Furthermore, it
allows the determination of cell number and conflu-
ence. An integrated image analysis algorithm makes it
possible to measure more than forty parameters of each
cell in a holographic image (cell volume, cell thickness,
cell shape convexity, cell perimeter length, cell optical
length, etc.) which reflects cytotoxicity [37]. During apop-
tosis, cell membrane permeability increases and the op-
tical density of cells decreases, this changes their texture
and the contrast becomes lower (http://www.phiab.se/
products/holomonitor).U87 MG glioma cells were exposed to 25 μM AA, 25
μM DHA or 50 μM GLA alone or in combination with
irradiation (10 Gy) and holographic and phase contrast
images were recorded to detect morphological alter-
ations following treatment (Figure 6).
Our results showed that PUFAs as adjuncts to a dose of
10 Gy significantly diminished cell number, confluence,
and average cell irregularity, while average cell thickness
increased significantly (Figure 7). The latter described pa-
rameters indicate cell rounding and loss of adherence,
which indicates that the treatment had a cytotoxic effect
on U87 MG cells.
Our results concerning cell number, confluence, aver-
age cell thickness and average cell irregularity imply that
combined treatment of glioma cells with AA, DHA or
GLA and radiotherapy would have inhibitory effects on
invasion and metastasis.
Gene expression analysis of PUFA treated and irradiated
U87 MG cells
Several molecular targets for glioma treatment are sub-
jects of clinical trials and under development [5,29,38].
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tion of more than one molecular target could be a solution
for proper therapy. The foundations of an effective therapy
would be the better knowledge of the affected genes and
miRNAs in glioma pathogenesis. Because PUFAs are sup-
posed to be radio sensitizing agents in glioblastoma treat-
ment, the mRNA and miRNA expression analysis presented
here emphasize several potential molecular targets (our re-
sults are summarized in Additional file 2: Table S3).
We found that AA, significantly increased c-MYC ex-
pression, just like 10 Gy, and combined exposure of U87
MG cells had an increased effect (Figure 8). Determination
of c-MYC expression may serve as a prognostic value in
glioblastoma, its expression was increased in approxi-
mately 70% of the cases [39]. Alteration of c-MYC expres-
sion influenced apoptosis, cell cycle progression and
carcinogenesis [40]. In Jurkat and Raji cells oleic acid and
linolenic acid induced over-expression of c-MYC after 24
hours [41,42]. On U87 MG cells we detected significant
over-expression only in case of treatment with 25 μM AA
(Figure 8). Although c-MYC is an oncogene, its overex-
pression is correlated with a higher survival probability
(P < 0.0001) [39]. This result suggests that combined
therapy of AA and irradiation may be beneficial for glio-
blastoma treatment (Figure 8).
According to previous findings DHA did not change the
total levels of TP53, impaired DNA binding of TP53 was
observed in endothelial cells [43]. Under our conditions
10 Gy significantly increased the expression of TP53 on
U87 MG cells, while GLA and DHA did not influence its
expression (Figure 8). If AA was added as adjunct to
radiotherapy the expression of TP53 was significantly de-
creased (Figure 8). In our previous paper we investigated
the effect of a three-four times higher concentration of
AA, DHA and GLA applied for a shorter incubation
period on glioma cell lines [7]. We found that they altered
the expression of TP53 in GBM5 and U373 glioma cell
lines, but not in GBM2 cell line [7], similarly to U87 MG
cells observed in the present study. Differences in TP53
expression changes could be due to the different TP53 sta-
tus, the variability of overall TP53 expression and relative
levels of isoforms as these differences in glioblastoma are
well documented [44].
One explanation of the beneficial effect of PUFAs
would be that they may increase the activity of antioxi-
dant enzymes [32]. The excess of reactive oxygen species
induce lipid peroxidation and hydroperoxide generation
in glioma cells, which decrease their viability and their
sensitivity to irradiation [6,32,45]. Therefore, we evalu-
ated the expression of HMOX1, AKR1C1 and NQO1
genes which have a role in the defense mechanism
against oxidative stress.
HMOX1 is a heat-shock protein; it degrades heme to
biliverdin, CO and iron [46]. HMOX1 inhibits apoptosisand inflammation, diminishes oxidative stress, enhances
the rate of proliferation and playes a role in resistance
to irradiation or chemotherapy [46-49]. HMOX1 is a po-
tential therapeutic target, it is over-expressed and facili-
tates angiogenesis in glioma and may influence the
outcome of the disease [47,50]. Irradiation induced
HMOX1 expression on pancreatic cancer cells [47]. We
observed the same effect when we irradiated U87 MG
cells with 10 Gy (Figure 8). Exposure to AA or DHA or 10
Gy combined with AA or with DHA also increased its ex-
pression in a significant manner (Figure 8).
AKR1C1 encodes a drug-metabolizing enzyme; the
level of expression of this gene may influence the prog-
nosis of different cancers [51]. Temozolomide treatment
significantly increased the expression of AKR1C1 in
U373 and T98G glioblastoma cells [51]. We noticed the
same effect when U87 MG cells were exposed to irradi-
ation and AA or GLA treatment (Figure 8).
When AA, DHA or GLA was added as adjunct, NQO1
expression increased significantly, and treatment with
DHA by itself also raised NQO1 expression. The exact
function of NQO1 in cancer genesis is not yet determined,
but it is known that it activates the apoptotic protein
TP53 and it is a priority target of glioblastoma chemother-
apy [52,53].
In our study combined treatment of 50 μM GLA and
irradiation reduced significantly the over-expression of
NOTCH1 which could be recorded when cells were sub-
jected only to GLA or they were only irradiated (Figure 8).
The main setback in radiotherapy is the radioresistance of
cancer stem cells, which may be attributed to the Notch
signaling pathway [5,29]. Altered Notch activity was de-
tected in several types of tumors; it mediates self-renewal
of glioblastoma and influences the response to radiother-
apy [5,29,54].
Endoplasmic reticulum (ER) stress response may be an
indicator of the efficiency of glioma treatment [55-57].
We evaluated both elements of the ER stress response:
the prosurvival arm (unfolded protein response (UPR)
pathway) which is responsible for the alleviation of ER
stress, and the proapoptotic arm, which is activated in
case of intensive stress, when the UPR pathway is over-
whelmed. The UPR pathway is represented by GRP78,
while DDIT3 (GADD153) stands for the proapoptotic
arm of the ER stress response [55-58]. Under our condi-
tions significant over-expression of GRP78 could be re-
corded when U87 MG cells were treated with AA or
DHA alone, or when cells were irradiated. Similar up-
regulation could be observed when cells were treated in
combination with irradiation and AA, DHA or GLA
(Figure 8).
GRP78 silencing delays glioma cell growth and sensi-
tizes human glioblastoma cell lines to chemotherapy
[56,58]. GRP78 is a prognostic marker; overexpression of
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Combination of PUFA treatment with irradiation did
not decrease the overexpression of GRP78 or of DDIT3
(Figure 8), thus it seems that PUFAs radio sensitize U87
MG cells through other pathways than the ER stress
response.
We examined the expression of EGR1, TNF-α, c-FOS
and FOSL1 that were proven to be early-response genes
and were up-regulated due to ionizing radiation: [59]. c-
FOS, EGR1 and FOSL1 contains a region with a serum re-
sponse element (SRE) as promoter, which is responsible
for the sensitivity of these genes to ionizing radiation
[59,60]. Ionizing radiation induces reactive oxygen species
and up-regulates EGR1, a zinc-finger protein with six
CArG elements, which regulates the transcription of genes
involved in differentiation and cell growth [59-61]. AA,
DHA and GLA up-regulated EGR1 and treatment with
GLA enhanced the effect of irradiation (Figure 8). In con-
trast, co-exposure with AA and 10 Gy increased EGR1 ex-
pression in a significantly lower manner than application
of 10 Gy by itself (Figure 8).
TNF-α is a growth promoting cytokine, which deter-
mines the outcome of glioblastoma [62]. At low TNF-α
concentration glioma cells have a higher survival rate,
while overexpression of TNF-α induces neuronal cell death
[62]. Irradiation alone, and combined with DHA and GLA
increased TNF-α expression significantly (Figure 8). AA
treatment of irradiated U87 MG cells significantly de-
creased the overexpression of TNF-α compared to cells
that were only irradiated (Figure 8). Thus, it seems that
AA diminishes the harmful effect caused by irradiation in-
duced TNF-α over-expression. Thus, this ω-6 fatty acid
may have therapeutic effect when it is combined with ir-
radiation, reducing possible side-effects.
In our study treatment of U87 MG cells with 25 μM
AA, 50 μM GLA; irradiation or exposure to 10 Gy and
PUFAs significantly increased the expression of FOSL1
compared to control cells (Figure 9). Overexpression of
FOSL1 may cause carcinogenesis, and is a typical charac-
teristic of glioma [63]. FOSL1 over-expression induced
differentiation, inhibited proliferation, growth and re-
duced tumorogenicity of C6 glioma cell line, so it may
be a potential target for glioma treatment [64].
c-FOS also contains serum response elements in its pro-
moter [59,60]. c-FOS, is an oncogenic transcription factor,
which regulates PKC-mediated signaling pathways [59],
and it can induce carcinogenesis [65]. Just as in case of
TNF-α, when we treated U87 MG cells with 25 μM AA, it
significantly decreased the overexpression of c-FOS, which
is otherwise induced by irradiation (Figure 9).
GADD45A is a target for therapeutic interventions in
cancer [66]. Exposure to 25 μM AA or 10 Gy signifi-
cantly increased the expression of GADD45A (Figure 9).
As a consequence of GADD45A overexpression TP53is phosphorylated and it stabilizes TP53 after DNA
damage [66].
While different tumor types present specific micro-
RNA signatures, several microRNAs are deregulated in
glioblastoma, suggesting their involvement in the basic
processes of tumorigenesis and response to therapy [67].
To further analyze the mechanism of action of AA,
DHA and GLA in combination with irradiation, miRNA
expression levels were evaluated. Irradiation with 10 Gy
and PUFA treatment did not alter significantly the ex-
pression of miR-34a, miR-96, miR-148a, miR-148b and
miR-152. However, when cells were treated with DHA
miR-146a was significantly up-regulated. Interestingly,
its expression decreased when it was exposed to GLA.
In case of combined exposure to irradiation and GLA
the expression of miR-146a increased significantly com-
pared with GLA alone or with irradiation. Recently it
was shown that miR-146a suppresses gastric cancer cell
invasion and metastasis in vitro and in vivo [68]. From
our data it would be interesting to investigate the dif-
ferential effects of DHA and GLA on miR-146a in
relevance with metastatic potential of glioblastoma, es-
pecially that GLA was the only PUFA which, in combin-
ation with radiation, could induce its expression suggesting
potent antimetastatic effects.
Conclusions
Our biophysical, biochemical assays, 3D morphological
and gene expression analysis confirmed that PUFA treat-
ment enhances the radiosensitivity of glioma cells. Ir-
radiation and PUFA treatment influenced significantly
the expression of several potential therapeutic targets,
EGR1, HMOX1, NOTCH1, GADD45A and NQO1, in a
favorable manner. Based on our results, out of the five
investigated UFAs (AA, DHA, GLA, EPA and OA) AA
and GLA had the most significant additive cytotoxic ef-
fects with irradiation. However, for therapeutic applica-
tions further investigations are necessary.
Material and methods
Cell lines and culturing conditions
U87 MG (ATCC HTB-14TM) glioma cells were cultured at
37°C in 5% CO2 atmospheric pressure in DMEM supple-
mented with 10% FCS. Cells were plated in 16-well e-
plates (Roche, Hungary), 96-well culture plates, T25 or
T100 flasks at various densities depending on the type and
set-up of the experiment. UFAs were administered 1 hour
prior to irradiation. The added UFAs were present in the
medium throughout the whole incubation interval, 24, 48,
72 or 100 hours, respectively. The UFAs could incorporate
into the membranes or enter the cell until the end of the
experiment. Cells were treated with the following UFAs:
AA (Cayman Chemical Company, San Diego, California),
EPA (Sigma-Aldrich, Budapest, Hungary), DHA (Cayman
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Hungary), OA (Sigma-Aldrich). Then cells were sub-
jected to a dose of 5 or 10 Gy and incubated for 24, 48
or 72 hours.
Irradiation
A Teragam K-01 cobalt unit was used (average energy
1.25MeV, SID = 80 cm) to irradiate cells dispensed in tis-
sue culture plates and flasks. The plates or flasks were
surrounded by water equivalent material at each side
and placed between two PMMA slabs of 2 cm thickness
to ensure the necessary build-up material. The isocenter
was positioned in the geometrical centers of the plates.
One half of the planned dose was delivered with a down-
ward 20 × 20 cm beam (gantry angle 0 degrees), while
the other half with an upward beam (gantry angle 180
degrees) to maximize the field homogeneity. The deliv-
ered doses were 0, 5 and 10 Gy respectively. Irradiation
time correction factors due to the decay of the cobalt-60
source have been applied.
Biochemical assays
LDH assay
U87 MG cells were seeded at 2000 cells/well density, in-
cubated for 24 hours, treated with UFAs and one hour
later, exposed to irradiation. 72 hours later media was
removed from the wells and cells were washed with PBS.
Following total cell lysis with 70 μL of 1% Triton X-100
(Sigma-Aldrich) in PBS, 70 μL LDH reagent was added
(Roche). After 10 minutes, absorbance was measured at
490 nm.
MTS assay
Plating, treatment and incubation period was the same as
in the case of the LDH assay. After 72 hour incubation,
20 μL of PMS:MTS (1:20) solution was added to the cells.
1 hour later, absorbance was measured at 490 nm.
xCELLigence assay
Impedance based real-time cell electronic sensing (RT-
CES) assay was performed with xCELLigence RTCA in-
strument [24]. Cells were plated in 16-well e-plates at
2000 cells/well density. Next day cells were treated with
UFAs, irradiated and monitored for 72 hours. Measure-
ments were recorded every 10 minutes. Cell index values
were normalized to the time point prior to UFA treatment.
Holographic imaging
For holographic imaging 600,000 cells were plated in
T25 flasks. 24 hours later the corresponding cells were
exposed to a dose of 10 Gy and/or pre-treated with 25
μM AA, 25 μM DHA or 50 μM GLA and further incu-
bated for 48 hours. Images were recorded with HoloMo-
nitor™ M3 (Phase Holographic Imaging AB, Lund,Sweden). Phase contrast and holographic images were
taken of three representative frames. The software of the
apparatus counts cells and uses specific algorithms to
define their outlines. It measures 43 parameters, for each
cell, e.g.: confluence, cell area, cell optical path length,
cell roughness, texture, volume, irregularity, etc.
All integral cells were taken into consideration in all
frames. We applied paired Student’s t-test for signifi-
cance analysis.
Samples for gene and miRNA expression
600,000 U87 MG cells were seeded in T100 flasks and
incubated for 24 hours. Cells were pre-treated with 25
μM AA, 25 μM DHA or 50 μM GLA and subjected to
irradiation.
Nucleic acid isolation
Columns, binding buffer and wash buffer were used from
the Viral RNA extraction kit (Bioneer, Daejon, South
Korea). Binding buffer 1 (2:1 etanol: binding buffer) and
binding buffer 2 (5:1 etanol: binding buffer) was prepared.
Cells were washed with PBS, incubated in lysis buffer
(Accuzol™ Total RNA Extraction Solution, Bioneer, Daejon)
for 5 minutes. The lysate was collected. The upper aqueous
phase was collected after addition of dichloromethane.
Binding buffer 1 was added to the sample, and then trans-
ferred through columns. The flow-through was collected
for miRNA isolation as described previously [25]. The col-
umns were treated with DNase (Omega bio-tek, Norcross,
Georgia, USA). Binding buffer 2 was added to the flow-
through, and the mixture was transferred through another
binding column. After two subsequent washing steps, RNA
and miRNA was eluted in RNase free-water.
The quality and quantity of the isolated miRNA and
RNA was measured with NanoDrop1000 Version 3.8.1.
(Thermo Fisher Scientific, Wilmington, USA).
RNA expression
Reverse transcription from total RNA was performed with
the High Capacity cDNA Reverse Transcription Kit as rec-
ommended by Applied Biosystems® (Life Technologies,
Foster City, CA, USA). cDNA was diluted 18 times. Gene
expression was measured with Platinum SYBR Green
qPCR SuperMix (Invitrogen). 4.5 μL template cDNA was
added to 5.5 μL Mastermix. QRT-PCR was performed on
a RotorGene 3000 instrument (Corbett Life Science, QIA-
GEN) with gene-specific primers as previously described
[69]. Primer sequences are presented in Additional file 3:
Table S1. The final primer concentration was 250 nM. Ct
values were determined with Rotor-Gene Version 6.0
(Corbett Life Science). The PCR protocol was the follow-
ing: 1. 95°C 2 min; 2. 95°C 15 sec; 3. 60°C 45 sec; with 60
cycles. After cycling melting curves were recorded. Primer
specificity was verified by comparing Tm values of the
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pression was normalized to HPRT1 and PPIA expression.
p-values were determined with Welch’s ttest.miRNA expression
200 ng miRNA was transcribed with 5x TaqMan RT assay
primer (Life Technologies) mix and high capacity cDNA
Reverse Transcription Kit (Life Technologies) with the fol-
lowing protocol: 1. 16°C 30 min; 42°C 30 min; 85°C 5 min.
miRNA expression was determined with FastStart Taq-
Man Probe Master (Roche) and with TaqMan primers (20x,
Life Technologies) with Exicycler 96 Real-Time Quantita-
tive Thermal Block (Bioneer). Reagent composition for one
sample is the following: 5 μL FastStart TaqMan Probe
Master; 3.5 μL water; 0.5 μL primer and 1 μL cDNA with
the following PCR protocol: heat-start at 95°C for 15 min;
50 cycles of 95°C for 15 sec; 60°C for 1 min.
Ct values of miRNA expression were normalized for
the median of all miRNA measured on the same sample.
Significance was determined with Welch’s t-test.Additional files
Additional file 1: Figure S1. miRNA expression analysis of PUFA
treated and irradiated glioma cell line. U87 MG cells were irradiated with
10 Gy, treated with polyunsaturated fatty acid (PUFAs) and incubated for
48 hours. miRNA expression was measured with RT-PCR. Abbreviations:
AA- 25 μM arachidonic acid; DHA - 25 μM docosahexaenoic acid;
GLA - 50 μM gamma linolenic acid. Abbreviations: */** - significant
(p < 0.05/ p < 0.01) difference between Ct values of control cells and
treated cells. #/## - significant (p < 0.05/ p < 0.01) difference between
cells exposed only to 10 Gy and U87 MG cells treated with PUFA and 10 Gy.
Additional file 2: Table S2. Summary of the effect of UFA treatment
on U87 MG glioma cell line detected by RT-CES, LDH and MTS assay.
Table S3. Summary of changes in cell morphology, in mRNA and in
miRNA expression due to PUFA treatment and/or irradiation.
Additional file 3: Table S1. List and sequence of primers used for gene
expression analysis.Abbreviations
AA: Arachidonic acid; DHA: Docosahexaenoic acid; miRNA: Micro RNA; MTS:
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy phenyl)-2-(4-sulfophenyl)-2H-
tetrazolium; EPA: Eicosapentaenoic acid; GLA: Gamma linolenic acid;
LDH: Lactate dehydrogenase; OA: Oleic acid; PUFA: Polyunsaturated fatty acids;
UFA: Unsaturated fatty acids.
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